Breaking Finance News

A statement released earlier today by Zacks Investment Research about Grifols SA, Barcelona (NASDAQ:GRFS) bumps the target price to $18.00

Having a price of $16.03, Grifols SA, Barcelona (NASDAQ:GRFS) traded -0.37% lower on the day. With the last stock price up 0.10% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. GRFS has recorded a 50-day average of $16.25 and a two hundred day average of $16.01. Trade Volume was down over the average, with 357,696 shares of GRFS changing hands under the typical 751,659

In a report announced on 9/28/2016 Zacks Investment Research raised the target price of Grifols SA, Barcelona (NASDAQ:GRFS) to $18.00 reporting a potential upside of 0.12%.

On 8/17/2015, JP Morgan released a statement about Grifols SA, Barcelona (NASDAQ:GRFS) upped the target price from $35.00 to $38.00 that suggested an upside of 0.19%.

Recent Performance Chart

Grifols SA, Barcelona (NASDAQ:GRFS)

Grifols SA, Barcelona has PE ratio of 36.56 with a one year low of $14.07 and a one year high of $18.04 and has a market capitalization of $0.

General Company Details For Grifols SA, Barcelona (NASDAQ:GRFS)

Grifols, S.A., a biopharmaceutical company, develops, manufactures, and distributes plasma derivative products in the United States, Canada, Spain, rest of the European Union, and internationally. It specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation, and reagents for use in hospitals and clinics. The company operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, which include IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by and in hospitals, such as parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.